

CHU de Nice

[View the current CHU de Nice Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/20913-CHU+de+Nice.html)

(<http://www.bioportfolio.com/biocorporate/20913-CHU+de+Nice.html>)

Contact Details:

Tel: 04 92 03 41 03

Fax:

Email: robiquet.g@chu-nice.fr

Nil

Recent Publications by CHU de Nice:



- [Immune changes in post-menopausal osteoporosis: the Immunos study.](#)
*The phenotypic and functional characteristics of immune cells of...*31st October, 2009
Service de Rhumatologie, CHU de Nice, Hopital l'Archet, Route Saint- Osteoporos Int. 2009 Oct 30. ([DOI Direct Link](#))
- [An Analysis of the French Multicentre Experience of Fenestrated Aortic Endografts: Medium-Term Outcomes.](#)
*PURPOSE:: To evaluate the medium-term outcomes following aortic aneurysm...*30th October, 2009
From the *Department of Vascular Surgery, Hopital Cardiologique, CHRU de- Ann Surg. 2009 Oct 27. ([DOI Direct Link](#))
- [\[Expert's formalized recommendations. Glycemic control in ICU and during anaesthesia: useful recommendations\]](#)
*Neonatal jaundice resulting from immunological hemolysis is not uncommon....*24th October, 2009
Service de Reanimation Medicochirurgicale, Hopital Saint-Roch, CHU de- Ann Fr Anesth Reanim. 2009 Jul-Aug;28(7-8):717-8. Epub 2009 Jul 7. ([DOI Direct Link](#))
- [\[Natalizumab \(Tysabri\(\(R\)\)\) prescription practices of neurologists in southern France.\]](#)
*INTRODUCTION: Tysabri((R)) is indicated as single-drug disease-modifying...*23rd October, 2009
Service de neurologie, hopital Pasteur, CHU de Nice, 30, venue de la voie- Rev Neurol (Paris). 2009 Oct 19. ([DOI Direct Link](#))
- [\[Dengue fever: clinical features\]](#)
*The vector for dengue fever and chikungunya, Aedes albopictus, was...*20th October, 2009
Universite de Nice-Sophia-Antipolis, Service Infectiologie, Hopital Archet- Arch Pediatr. 2009 Oct;16 Suppl 2:S80-4. ([DOI Direct Link](#))
- [\[Prospective evaluation of antibiotic combinations in a general hospital.\]](#)

- INTRODUCTION: We previously reported a 30% rate of inadequate antibiotic...*3rd October, 2009
Service d'infectiologie, hopital de l'Archet-1, CHU de Nice, BP 3079,- Med Mal Infect. 2009 Sep 29. ([DOI Direct Link](#))
- [\[Visual loss in a 51-year-old woman.\]](#)
*INTRODUCTION: We previously reported a 30% rate of inadequate antibiotic...*8th September, 2009
Service de medecine interne, hopital Archet-I, CHU de Nice, 151, route de- Rev Med Interne. 2009 Oct;30(10):896-9. Epub 2009 Sep 4. ([DOI Direct Link](#))
 - [\[Oncogeriatrics: the geriatrician's point of view\]](#)
*The problem of the oncogeriatrics is a real challenge for next decades....*25th August, 2009
Pole de Gerontologie, Universite de Nice Sophia-Antipolis, Hopital de- Cancer Radiother. 2009 Oct;13(6-7):606-8. Epub 2009 Aug 21. ([DOI Direct Link](#))
 - [\[Management of acute retinal necrosis syndrome with cystoid macular edema: a case report\]](#)
*Acute retinal necrosis is a rare but devastating and rapidly progressive...*25th August, 2009
Service d'ophtalmologie, CHU de Nice, Hopital Saint Roch, Nice, France.- J Fr Ophtalmol. 2009 Jan;32(1):60.e1-6. Epub 2009 Feb 4. ([DOI Direct Link](#))
 - [\[Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.\]](#)
*OBJECTIVES:: Progressive liver injury is a concern in HIV-infected...*12th August, 2009
Service de Physiologie et Explorations Fonctionnelles Pediatriques, Pole- J Pediatr Gastroenterol Nutr. 2009 Nov;49(5):599-606. ([DOI Direct Link](#))
 - [\[Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition?\]](#)
*A decrease in sensory nerve action potentials (SNAP) amplitude has been...*31st July, 2009
Centre de reference pour Maladies NeuroMusculaires et SLA, Hopital Archet- J Neurol. 2009 Nov;256(11):1876-80. Epub 2009 Jul 30. ([DOI Direct Link](#))
 - [\[Key drugs and doses in the hypertension's treatment in child in France\]](#)
*The prescription drug for hypertension in children remains difficult...*25th July, 2009
Pole pharmacie, hopital de l'Archet, CHU de Nice, 15 route de- Arch Pediatr. 2009 Oct;16(10):1419-23. Epub 2009 Jul 21. ([DOI Direct Link](#))
 - [\[Allergic and nonallergic hypersensitivity reactions to silicone: a report of one case.\]](#)
*The prescription drug for hypertension in children remains difficult...*25th July, 2009
Universite de Nice Sophia Antipolis, Pole Enfant Adolescent, CHU de Nice,- Allergy. 2009 Oct;64(10):1555. Epub 2009 Jul 17. ([DOI Direct Link](#))
 - [\[High-dose intravenous immunoglobulin therapy and neonatal jaundice due to red blood cell alloimmunization\]](#)
*Neonatal jaundice resulting from immunological hemolysis is not uncommon....*10th July, 2009
Service de medecine neonatale, hopital de l'Archet-II, CHU de Nice, Nice- Arch Pediatr. 2009 Sep;16(9):1289-94. Epub 2009 Jul 7. ([DOI Direct Link](#))
 - [\[Epidemiology of amyotrophic lateral sclerosis\]](#)
*Amyotrophic lateral sclerosis (ALS) is the most common motor neuron...*16th June, 2009
Centre de reference maladies neuromusculaires, SLA, hopital Archet, CHU de- Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):627-40. Epub 2009 Jun 13. ([DOI Direct Link](#))

Press Releases on CHU de Nice:

[New Survey Shows Substantial Growth and Some Challenges with Electronic Data Capture in Clinical Trials](#) 19th October, 2009

NICE, France, October 19 /PRNewswire/ -- Preliminary findings from a new survey on electronic data capture (EDC) use in clinical trials were presented today at the Drug Information Association's

New Report Just Published: World Prostate Cancer Therapeutics Market Report	7th July, 2009	Reportlinker	<p>NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Prostate Cancer Therapeutics Market http://www.reportlinker.com/p0119471/World</p>
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice	3rd June, 2009	PeriCor Therapeutics, Inc.	<p>Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that</p>
Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service	2nd June, 2009	Nice Systems Ltd.	<p>RA'ANANA, Israel, June 2 /PRNewswire-FirstCall/ -- NICE Systems Ltd. (NASDAQ: NICE), the global provider of advanced solutions that enable organizations to extract Insight from Interactions</p>
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables	1st June, 2009	Corthera Inc.	<p>Data from Phase II/III Study Presented at Heart Failure Congress 2009 Demonstrate Promising Safety and Efficacy Results for Relaxin SAN MATEO, Calif. June 1 /PRNewswire/ -- Corthera Inc. today</p>

BioNews Results for CHU de Nice



- [Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children \[Pediatric Oncology\]](#)
Journal of Clinical Oncology: Oct 31 2009 5:47PM Matching: chu de nice

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to

your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

